A late-stage trial on the use of aflibercept in combination with gemcitabine as first-line treatment of pancreatic cancer was discontinued because of disappointing results. The drugmakers said they will continue testing aflibercept's effectiveness against metastatic colorectal cancer, metastatic prostate cancer and nonsmall-cell lung cancer.

Full Story:

Related Summaries